VistaGen Therapeutics (VTGN) Financials

VistaGen Therapeutics (NASDAQ: VTGN) remains a development-stage biotech with very limited revenue and significant operating losses, but its balance sheet still shows a meaningful cash position. Over the last four years, the main story is consistent: revenue has been small and uneven, while research and development spending has stayed high, keeping the company deeply unprofitable.

In the most recent quarter, Q4 2026, revenue was just $464,000, while operating expenses totaled $17.2 million. That led to an operating loss of $16.7 million and a net loss of $16.3 million. While losses are still large, they were somewhat better than Q3 2026, when the company reported a net loss of $18.9 million.

One encouraging trend is that quarterly revenue has been gradually improving from the low- to mid-$200,000 range in early 2025 to the mid-$400,000 range by Q4 2026. That said, the absolute level of revenue is still far too small to offset expenses, so the company is not yet close to profitability.

Operating costs remain the biggest issue. R&D spending has generally stayed elevated, reflecting ongoing clinical development, but it also keeps cash burn high. SG&A has fluctuated quarter to quarter, but total operating expenses have stayed in the tens of millions per quarter, which is typical for a clinical-stage biotech but still a major risk for investors.

Cash flow trends show that VistaGen is still burning substantial cash from operations. In Q4 2026, operating cash flow was negative $16.2 million. For the full recent sequence of quarters, operating cash burn has generally ranged from about $10 million to nearly $19 million per quarter, underscoring the company’s dependence on external funding or balance-sheet liquidity.

The balance sheet is stronger than the income statement. At Q3 2026, VistaGen reported $47.4 million in cash and equivalents and $14.4 million in short-term investments, for a total liquidity cushion of about $61.8 million. That was down from $77.2 million in Q2 2026 and $89.1 million in Q1 2026, showing the impact of ongoing cash burn.

Equity issuance has been an important funding source. In several quarters, cash from financing activities was positive because the company issued common stock. This helps support operations, but it also suggests continued dilution risk for existing shareholders.

• Liquidity remains solid for now: VistaGen still held meaningful cash and investments in the most recent reported balance sheet period.
• Revenue is trending upward: Quarterly revenue has improved from the low-$200,000s in 2025 to $464,000 in Q4 2026.
• Recent net loss improved sequentially: Q4 2026 net loss narrowed versus Q3 2026.
• Interest and investment income helps cushion losses: Non-operating income has provided a modest offset to operating losses.
• Development-stage profile remains intact: High R&D spending suggests the company is still investing in pipeline progress.
• Operating losses remain very large: Revenue is nowhere near enough to cover expenses.
• Cash burn is significant: Operating cash flow has been negative every quarter shown.
• Share dilution is a risk: Common equity issuance has frequently funded operations.
• Balance-sheet cash is declining: Liquidity has fallen meaningfully from early 2026 levels.
• No clear path to profitability yet: The company is still far from breakeven on both an operating and net-income basis.

Bottom line: VTGN has enough balance-sheet strength to keep operating in the near term, but the business still looks highly speculative. Investors will likely be focused on clinical progress and whether the company can eventually translate its pipeline into meaningful revenue, because the current financial model is still built around losses and cash burn.